http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 22 Jun 2026 12:00:12 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Stock+Buybacks/Aelis+Farma+discloses+share+buyback+program+details/26671807.html <p>Aelis Farma (Euronext Paris: AELIS), a clinical-stage biopharmaceutical company, has made available the description of its share buyback program, following authorization granted at the company's Annual General Meeting on June 3, 2026.</p> <p>The buyback program was authorized under the 12th resolution of the Combined General Meeting, pursuant to Article L. 22-10-62 of the French Commercial Code. The Board of Directors was granted powers to implement the program, with the ability to subdelegate in accordance with applicable law.</p> <p>In accordance with Article 241-3 of the General Regulation of the Autorité des Marchés Financiers (AMF), the program description is included in the company's Universal http://www.streetinsider.com/Stock+Buybacks/Aelis+Farma+discloses+share+buyback+program+details/26671807.html Mon, 22 Jun 2026 12:00:12 -0400 AELIS O.16864920 http://www.streetinsider.com/Stock+Buybacks/Aelis+Farma+discloses+share+buyback+program+details/26671807.html <p>Aelis Farma (Euronext Paris: AELIS), a clinical-stage biopharmaceutical company, has made available the description of its share buyback program, following authorization granted at the company's Annual General Meeting on June 3, 2026.</p> <p>The buyback program was authorized under the 12th resolution of the Combined General Meeting, pursuant to Article L. 22-10-62 of the French Commercial Code. The Board of Directors was granted powers to implement the program, with the ability to subdelegate in accordance with applicable law.</p> <p>In accordance with Article 241-3 of the General Regulation of the Autorité des Marchés Financiers (AMF), the program description is included in the company's Universal http://www.streetinsider.com/Stock+Buybacks/Aelis+Farma+discloses+share+buyback+program+details/26671807.html Mon, 22 Jun 2026 12:00:12 -0400 AELIS O.16864920 http://www.streetinsider.com/Press+Releases/Aelis+Farma%3A+Availability+of+the+Description+of+the+Share+Buyback+Program/26671799.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces the availability of the description of the share buyback program authorized by the Annual General Meeting of June 3, 2026. </p><p> Pursuant to Article L. 22-10-62 et seq. of the French Commercial Code, the Combined General Meeting of shareholders authorized the Board of Directors, on June 3, 2026, in its 12th resolution, to implement a share buyback program of the Company, with powers to subdelegate in accordance with http://www.streetinsider.com/Press+Releases/Aelis+Farma%3A+Availability+of+the+Description+of+the+Share+Buyback+Program/26671799.html Mon, 22 Jun 2026 12:00:00 -0400 AELIS O.16864920 http://www.streetinsider.com/Press+Releases/Aelis+Farma%3A+Availability+of+the+Description+of+the+Share+Buyback+Program/26671799.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces the availability of the description of the share buyback program authorized by the Annual General Meeting of June 3, 2026. </p><p> Pursuant to Article L. 22-10-62 et seq. of the French Commercial Code, the Combined General Meeting of shareholders authorized the Board of Directors, on June 3, 2026, in its 12th resolution, to implement a share buyback program of the Company, with powers to subdelegate in accordance with http://www.streetinsider.com/Press+Releases/Aelis+Farma%3A+Availability+of+the+Description+of+the+Share+Buyback+Program/26671799.html Mon, 22 Jun 2026 12:00:00 -0400 AELIS O.16864920 http://www.streetinsider.com/Business+Wire/Aelis+Farma%3A+Availability+of+the+Description+of+the+Share+Buyback+Program/26671799.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces the availability of the description of the share buyback program authorized by the Annual General Meeting of June 3, 2026. </p><p> Pursuant to Article L. 22-10-62 et seq. of the French Commercial Code, the Combined General Meeting of shareholders authorized the Board of Directors, on June 3, 2026, in its 12th resolution, to implement a share buyback program of the Company, with powers to subdelegate in accordance with http://www.streetinsider.com/Business+Wire/Aelis+Farma%3A+Availability+of+the+Description+of+the+Share+Buyback+Program/26671799.html Mon, 22 Jun 2026 12:00:00 -0400 AELIS O.16864920 http://www.streetinsider.com/Business+Wire/Aelis+Farma%3A+Availability+of+the+Description+of+the+Share+Buyback+Program/26671799.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces the availability of the description of the share buyback program authorized by the Annual General Meeting of June 3, 2026. </p><p> Pursuant to Article L. 22-10-62 et seq. of the French Commercial Code, the Combined General Meeting of shareholders authorized the Board of Directors, on June 3, 2026, in its 12th resolution, to implement a share buyback program of the Company, with powers to subdelegate in accordance with http://www.streetinsider.com/Business+Wire/Aelis+Farma%3A+Availability+of+the+Description+of+the+Share+Buyback+Program/26671799.html Mon, 22 Jun 2026 12:00:00 -0400 AELIS O.16864920 http://www.streetinsider.com/Press+Releases/Results+of+Aelis+Farma+Combined+General+Meeting+of+June+3%2C+2026/26604335.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders. </p><p> Aelis Farma held its combined general meeting of shareholders on June 3, 2026, which was chaired by Mr. Anders Gersel Pedersen, Chairman of the Board of directors. </p><p> With a quorum of 63.17%, the shareholders have adopted all the resolutions recommended by the Board of Directors, in particular the financial http://www.streetinsider.com/Press+Releases/Results+of+Aelis+Farma+Combined+General+Meeting+of+June+3%2C+2026/26604335.html Thu, 04 Jun 2026 12:00:00 -0400 AELIS O.16864920 http://www.streetinsider.com/Press+Releases/Results+of+Aelis+Farma+Combined+General+Meeting+of+June+3%2C+2026/26604335.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders. </p><p> Aelis Farma held its combined general meeting of shareholders on June 3, 2026, which was chaired by Mr. Anders Gersel Pedersen, Chairman of the Board of directors. </p><p> With a quorum of 63.17%, the shareholders have adopted all the resolutions recommended by the Board of Directors, in particular the financial http://www.streetinsider.com/Press+Releases/Results+of+Aelis+Farma+Combined+General+Meeting+of+June+3%2C+2026/26604335.html Thu, 04 Jun 2026 12:00:00 -0400 AELIS O.16864920 http://www.streetinsider.com/Business+Wire/Results+of+Aelis+Farma+Combined+General+Meeting+of+June+3%2C+2026/26604335.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders. </p><p> Aelis Farma held its combined general meeting of shareholders on June 3, 2026, which was chaired by Mr. Anders Gersel Pedersen, Chairman of the Board of directors. </p><p> With a quorum of 63.17%, the shareholders have adopted all the resolutions recommended by the Board of Directors, in particular the financial http://www.streetinsider.com/Business+Wire/Results+of+Aelis+Farma+Combined+General+Meeting+of+June+3%2C+2026/26604335.html Thu, 04 Jun 2026 12:00:00 -0400 AELIS O.16864920 http://www.streetinsider.com/Business+Wire/Results+of+Aelis+Farma+Combined+General+Meeting+of+June+3%2C+2026/26604335.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders. </p><p> Aelis Farma held its combined general meeting of shareholders on June 3, 2026, which was chaired by Mr. Anders Gersel Pedersen, Chairman of the Board of directors. </p><p> With a quorum of 63.17%, the shareholders have adopted all the resolutions recommended by the Board of Directors, in particular the financial http://www.streetinsider.com/Business+Wire/Results+of+Aelis+Farma+Combined+General+Meeting+of+June+3%2C+2026/26604335.html Thu, 04 Jun 2026 12:00:00 -0400 AELIS O.16864920 http://www.streetinsider.com/Press+Releases/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, informs its shareholders and the financial community that the Company’s Combined General Meeting will be held on <b>Wednesday, June 3, 2026, </b>at <b>2 p.m.</b>, at <b>IECB, 2 rue Robert Escarpit, 33607 Pessac</b>. </p><p> The notice of the meeting, including the agenda and draft resolutions as well as the terms and conditions of participation and voting at the meeting, was posted on the website of the <i>Bulletin des Annonces Légales http://www.streetinsider.com/Press+Releases/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html Wed, 13 May 2026 12:00:00 -0400 A.00578948 A.26800952 AELIS O.00711722 O.08573398 O.16864920 http://www.streetinsider.com/Press+Releases/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, informs its shareholders and the financial community that the Company’s Combined General Meeting will be held on <b>Wednesday, June 3, 2026, </b>at <b>2 p.m.</b>, at <b>IECB, 2 rue Robert Escarpit, 33607 Pessac</b>. </p><p> The notice of the meeting, including the agenda and draft resolutions as well as the terms and conditions of participation and voting at the meeting, was posted on the website of the <i>Bulletin des Annonces Légales http://www.streetinsider.com/Press+Releases/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html Wed, 13 May 2026 12:00:00 -0400 A.00578948 A.26800952 AELIS O.00711722 O.08573398 O.16864920 http://www.streetinsider.com/Press+Releases/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, informs its shareholders and the financial community that the Company’s Combined General Meeting will be held on <b>Wednesday, June 3, 2026, </b>at <b>2 p.m.</b>, at <b>IECB, 2 rue Robert Escarpit, 33607 Pessac</b>. </p><p> The notice of the meeting, including the agenda and draft resolutions as well as the terms and conditions of participation and voting at the meeting, was posted on the website of the <i>Bulletin des Annonces Légales http://www.streetinsider.com/Press+Releases/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html Wed, 13 May 2026 12:00:00 -0400 A.00578948 A.26800952 AELIS O.00711722 O.08573398 O.16864920 http://www.streetinsider.com/Press+Releases/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, informs its shareholders and the financial community that the Company’s Combined General Meeting will be held on <b>Wednesday, June 3, 2026, </b>at <b>2 p.m.</b>, at <b>IECB, 2 rue Robert Escarpit, 33607 Pessac</b>. </p><p> The notice of the meeting, including the agenda and draft resolutions as well as the terms and conditions of participation and voting at the meeting, was posted on the website of the <i>Bulletin des Annonces Légales http://www.streetinsider.com/Press+Releases/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html Wed, 13 May 2026 12:00:00 -0400 A.00578948 A.26800952 AELIS O.00711722 O.08573398 O.16864920 http://www.streetinsider.com/Press+Releases/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, informs its shareholders and the financial community that the Company’s Combined General Meeting will be held on <b>Wednesday, June 3, 2026, </b>at <b>2 p.m.</b>, at <b>IECB, 2 rue Robert Escarpit, 33607 Pessac</b>. </p><p> The notice of the meeting, including the agenda and draft resolutions as well as the terms and conditions of participation and voting at the meeting, was posted on the website of the <i>Bulletin des Annonces Légales http://www.streetinsider.com/Press+Releases/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html Wed, 13 May 2026 12:00:00 -0400 A.00578948 A.26800952 AELIS O.00711722 O.08573398 O.16864920 http://www.streetinsider.com/Press+Releases/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, informs its shareholders and the financial community that the Company’s Combined General Meeting will be held on <b>Wednesday, June 3, 2026, </b>at <b>2 p.m.</b>, at <b>IECB, 2 rue Robert Escarpit, 33607 Pessac</b>. </p><p> The notice of the meeting, including the agenda and draft resolutions as well as the terms and conditions of participation and voting at the meeting, was posted on the website of the <i>Bulletin des Annonces Légales http://www.streetinsider.com/Press+Releases/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html Wed, 13 May 2026 12:00:00 -0400 A.00578948 A.26800952 AELIS O.00711722 O.08573398 O.16864920 http://www.streetinsider.com/Business+Wire/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, informs its shareholders and the financial community that the Company’s Combined General Meeting will be held on <b>Wednesday, June 3, 2026, </b>at <b>2 p.m.</b>, at <b>IECB, 2 rue Robert Escarpit, 33607 Pessac</b>. </p><p> The notice of the meeting, including the agenda and draft resolutions as well as the terms and conditions of participation and voting at the meeting, was posted on the website of the <i>Bulletin des Annonces Légales http://www.streetinsider.com/Business+Wire/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html Wed, 13 May 2026 12:00:00 -0400 A.00578948 A.26800952 AELIS O.00711722 O.08573398 O.16864920 http://www.streetinsider.com/Business+Wire/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, informs its shareholders and the financial community that the Company’s Combined General Meeting will be held on <b>Wednesday, June 3, 2026, </b>at <b>2 p.m.</b>, at <b>IECB, 2 rue Robert Escarpit, 33607 Pessac</b>. </p><p> The notice of the meeting, including the agenda and draft resolutions as well as the terms and conditions of participation and voting at the meeting, was posted on the website of the <i>Bulletin des Annonces Légales http://www.streetinsider.com/Business+Wire/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html Wed, 13 May 2026 12:00:00 -0400 A.00578948 A.26800952 AELIS O.00711722 O.08573398 O.16864920 http://www.streetinsider.com/Business+Wire/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, informs its shareholders and the financial community that the Company’s Combined General Meeting will be held on <b>Wednesday, June 3, 2026, </b>at <b>2 p.m.</b>, at <b>IECB, 2 rue Robert Escarpit, 33607 Pessac</b>. </p><p> The notice of the meeting, including the agenda and draft resolutions as well as the terms and conditions of participation and voting at the meeting, was posted on the website of the <i>Bulletin des Annonces Légales http://www.streetinsider.com/Business+Wire/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html Wed, 13 May 2026 12:00:00 -0400 A.00578948 A.26800952 AELIS O.00711722 O.08573398 O.16864920 http://www.streetinsider.com/Business+Wire/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, informs its shareholders and the financial community that the Company’s Combined General Meeting will be held on <b>Wednesday, June 3, 2026, </b>at <b>2 p.m.</b>, at <b>IECB, 2 rue Robert Escarpit, 33607 Pessac</b>. </p><p> The notice of the meeting, including the agenda and draft resolutions as well as the terms and conditions of participation and voting at the meeting, was posted on the website of the <i>Bulletin des Annonces Légales http://www.streetinsider.com/Business+Wire/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html Wed, 13 May 2026 12:00:00 -0400 A.00578948 A.26800952 AELIS O.00711722 O.08573398 O.16864920 http://www.streetinsider.com/Business+Wire/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, informs its shareholders and the financial community that the Company’s Combined General Meeting will be held on <b>Wednesday, June 3, 2026, </b>at <b>2 p.m.</b>, at <b>IECB, 2 rue Robert Escarpit, 33607 Pessac</b>. </p><p> The notice of the meeting, including the agenda and draft resolutions as well as the terms and conditions of participation and voting at the meeting, was posted on the website of the <i>Bulletin des Annonces Légales http://www.streetinsider.com/Business+Wire/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html Wed, 13 May 2026 12:00:00 -0400 A.00578948 A.26800952 AELIS O.00711722 O.08573398 O.16864920 http://www.streetinsider.com/Business+Wire/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, informs its shareholders and the financial community that the Company’s Combined General Meeting will be held on <b>Wednesday, June 3, 2026, </b>at <b>2 p.m.</b>, at <b>IECB, 2 rue Robert Escarpit, 33607 Pessac</b>. </p><p> The notice of the meeting, including the agenda and draft resolutions as well as the terms and conditions of participation and voting at the meeting, was posted on the website of the <i>Bulletin des Annonces Légales http://www.streetinsider.com/Business+Wire/Aelis+Farma%3A+Combined+General+Meeting+of+June+3%2C+2026%3A+Availability+of+Preparatory+Documents+and+Participation+and+Voting+Procedures/26484299.html Wed, 13 May 2026 12:00:00 -0400 A.00578948 A.26800952 AELIS O.00711722 O.08573398 O.16864920 http://www.streetinsider.com/Press+Releases/Aelis+Farma%3A+Availability+of+the+2025+Universal+Registration+Document/26364219.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces the publication of its 2025 Universal Registration Document (URD) as filed with the French Financial Markets Authority (<i>Autorité des Marchés Financiers </i>(AMF)) on April 23, 2026, under number D.26-0284. </p><p> The Universal Registration Document 2025 includes in particular: </p><ul class="bwlistdisc"> <li> The 2025 annual financial report; </li> <li> The statutory auditor’s reports; </li> <li> Information on the statutory auditor’s fees; </li> <li> Information relating to corporate social responsibility. </li> </ul><p> The URD can be consulted and downloaded on the Company’s website under http://www.streetinsider.com/Press+Releases/Aelis+Farma%3A+Availability+of+the+2025+Universal+Registration+Document/26364219.html Fri, 24 Apr 2026 12:00:00 -0400 A.00578948 A.26800952 AELIS O.00711722 O.08573398 O.16864920 http://www.streetinsider.com/Press+Releases/Aelis+Farma%3A+Availability+of+the+2025+Universal+Registration+Document/26364219.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces the publication of its 2025 Universal Registration Document (URD) as filed with the French Financial Markets Authority (<i>Autorité des Marchés Financiers </i>(AMF)) on April 23, 2026, under number D.26-0284. </p><p> The Universal Registration Document 2025 includes in particular: </p><ul class="bwlistdisc"> <li> The 2025 annual financial report; </li> <li> The statutory auditor’s reports; </li> <li> Information on the statutory auditor’s fees; </li> <li> Information relating to corporate social responsibility. </li> </ul><p> The URD can be consulted and downloaded on the Company’s website under http://www.streetinsider.com/Press+Releases/Aelis+Farma%3A+Availability+of+the+2025+Universal+Registration+Document/26364219.html Fri, 24 Apr 2026 12:00:00 -0400 A.00578948 A.26800952 AELIS O.00711722 O.08573398 O.16864920 http://www.streetinsider.com/Press+Releases/Aelis+Farma%3A+Availability+of+the+2025+Universal+Registration+Document/26364219.html <p> BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: </p><p> <b>Aelis Farma </b>(ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces the publication of its 2025 Universal Registration Document (URD) as filed with the French Financial Markets Authority (<i>Autorité des Marchés Financiers </i>(AMF)) on April 23, 2026, under number D.26-0284. </p><p> The Universal Registration Document 2025 includes in particular: </p><ul class="bwlistdisc"> <li> The 2025 annual financial report; </li> <li> The statutory auditor’s reports; </li> <li> Information on the statutory auditor’s fees; </li> <li> Information relating to corporate social responsibility. </li> </ul><p> The URD can be consulted and downloaded on the Company’s website under http://www.streetinsider.com/Press+Releases/Aelis+Farma%3A+Availability+of+the+2025+Universal+Registration+Document/26364219.html Fri, 24 Apr 2026 12:00:00 -0400 A.00578948 A.26800952 AELIS O.00711722 O.08573398 O.16864920